eTheRNA Immunotherapies NV is developing immunotherapy and vaccine products for the treatment of cancer and infectious disease from its multiple RNA, formulation and manufacturing technology platforms. The private company is headquartered in Belgium and was established in 2013. eTheRNA also has offices in New York and Hong Kong. To date, the Company has raised €63 million in venture capital.